Prior to the advent of anti-VEGF therapy, diabetic retinopathy was commonly treated with corticosteroid-based medications, which act in part by inhibiting phospholipase A2 and the formation of eicosanoids [34]. Here, VEGFA is linked to diabetic retinopathy.